


ENCALS

European Network to Cure ALS

June 17-20, 2024
Scientific Programme

ENCALS meeting 2024

Stockholm, Sweden



- Welcome to Stockholm..... 3
- Information for presenters..... 4
- General information..... 5
- Committee members 6
- Program at a glance..... 7
- Scientific programme8-13
- Sponsors 14
- Sponsor advertisement.....15-22

Welcome to Stockholm

Dear attendees of ENCALS,

I'm so very pleased to welcome you all to Stockholm this year for the ENCALS meeting 2024. It is an honor to organize this international meeting in Sweden. It has been more than a year since we started to organize this meeting, and I'm excited and thrilled to welcome you all. We are very happy for the nice program and thankful for the great speakers and look forward to listen to the latest scientific results in ALS research together with you!

The ENCALS meeting is a well visited international meeting aimed for young researchers to present their results. It is the mix of young and established researchers together with ALS-active companies, that makes the ENCALS meeting so unique. It is the perfect atmosphere for engaging stimulating discussions, creating collaborations and exchange knowledge.

It is our honor to welcome you at the Aula Medica, a beautifully designed building at the premises of Karolinska Institute. Designed by Wingårdh Arkitektkontor, this iconic structure was built to serve as a state-of-the-art lecture hall and event space for the university. The building's striking architecture features a modern glass facade that reflects the surrounding landscape, while its interior boasts cutting-edge technology and flexible seating arrangements to accommodate a variety of events and lectures. With its innovative design and functionality, the Aula Medica building has become a focal point of the Karolinska Institutet campus, embodying the institution's commitment to excellence in medical education and research. The actual room in which all presentations will take place, is a large amphitheater with a unique building structure; it is a pillar free hall with room for 1000 people. The auditorium is named after Erling Persson, founder of H&M, since the families generous donation in 2008 ensured the building.

During the conference we will stay at the Karolinska Institute, and enjoy lunch in the surroundings, and I am also thrilled to present a Swedish icon during the traditional Gala Dinner, namely the Vasa Museum. In this unique location the warship Vasa, an ancient ship located at the bottom of the ocean for 333 years until being rediscovered and salvaged, is now safely stored at the Vasa Museum, for everyone to see and experience. We promise a memorable experience!

My wish is for all of you to experience Swedish culture and research during the ENCALS conference, to persuade you that Sweden can do so much more than winning the Eurovision Song Contest. As you may (not) know, candy holds a special place in Swedish culture as an important treat enjoyed by Swedish people of all ages. Known as "smagodis," it plays a significant role in various traditions and celebrations, and its important to tell you that Swedes have a deep appreciation for these sweet delights that bring joy and sweetness to everyday life and counteracts the darkness during the winter months. To elevate your experience further and to make you feel like a real Swede, we have placed candystands at several places at the Aula Medica – your true Swedish experience is just about to begin!

Lastly, I want to thank all the sponsors for their support and all the members of the organizing committee for their dedication. This meeting wouldn't have been possible without them!

I hope you will all enjoy yourself in Stockholm!



- Caroline Ingre
Host and local organizer

Information for presenters

Poster details

- Pins and/or stickers will be provided
- You have to bring your poster with you (printed)
- All posters must be designed on A0 portrait size
- There are two different poster sessions, please ensure your poster is up during the right session.

Timing Presentations

- Plenary keynote speakers have 20 minutes + 5 minutes for questions
- Abstract presenters have 8 minutes + 2 minutes for questions
- Rapid fire presenters have 2 minutes + 1 minute for changing speaker. No questions. All Rapid fire presenters have a poster as well.

Technical presentation details presenters

- There is a speaker room available behind the stage.
- You must upload your presentation before the conference. The link is sent to you via email.
- Please design your PowerPoint presentation in format 16:9
- If you want to show a video, make sure to upload this video separately from your presentation



General information

Venue

Aula Medica at Karolinska Institutet
Nobels väg 6, 171 65 Stockholm

Directions and accessibility can be found on the [Karolinska Institutet website](#).

Contact:

Program, abstracts and general ENCALS:

Danique van der Gaauw - ENCALS office manager - info@encals.eu

Registrations, sponsorship and local information:

Matilda Jansson and Alexander Masalin - ENCALS2024@akademikonferens.se

Registrations

Deadline for registrations is May 31, 2024 (or earlier if we reach capacity). See [our website](#) for the registration link and registration categories.

Please note that on-site registration will not be possible.

Registration includes:

- Participation at all ENCALS lectures and poster sessions
- Lunch on Wednesday, Tuesday and Friday
- Coffee/tea and something savoury and/or sweet during the breaks
- ENCALS gala dinner - sponsored by ENCALS
- Access to the ENCALS meeting app with all the abstracts

ENCALS meeting app

Scan the QR code below to download.

Enter this password when prompted:

encals2024



App Store



Google Play

Main meeting

Accessibility

The Aula Medica is accessible for people in a wheelchair. Please notify the local organizers via ENCALS2024@akademikonferens.se before the meeting - to ensure we have enough space for people in a wheelchair in the main hall.

Dietary requirements

If you have indicated that you have special dietary requirements, please make yourself known to a member of staff.

General items

The registration desk will be staffed throughout the main meeting.

There will be a cloakroom on the second floor of Aula Medica. Please bring small bags to the conference (not bigger than A4 size). You can leave larger items at the cloakroom.

The dress code for the conference is smart casual, as is usual for ENCALS.

Gala dinner

The Gala dinner is held at [the Vasa Museum](#) (Galärvarvsvägen 14, Stockholm) on June 18 at 19:45 hrs. Here we will also take the group picture.

When you pick up your badge at the registration area, you will be given a ticket for the Gala dinner (if you added this at your registration). Please bring the ticket with you.

The temperature at the Vasa Museum is always 18 degrees to preserve the ancient ship. So don't forget to bring layers of clothing with you.

Committee members



Caroline Ingre, neurologist and head of ALS Center at Karolinska Institutet
Host and local organizer



Juliette Foucher, PhD Student, Clinical Neuroscience Department,
Karolinska Institutet
Clinical research coordinator, Karolinska University Hospital
Local organizer



Danique van der Gaauw
ENCALS office manager

Team Academic Conferences

- Matilda Jansson
- Alexander Masalin

Programme committee

Orla Hardiman (IR) - chair
Leonard van den Berg (NL)
Ammar Al-Chalabi (UK)
Monica Povedano (ES)
Sharon Abrahams (SC)
Jochen Weisenhaupt (GE)
Caroline Ingre (SE)
Ludo van den Bosch (BE)
Adriano Chio (IT)

Award Committee

Ammar Al-Chalabi (UK) - chair
Ludo van den Bosch (BE)
Luc Dupuis (FR)
Magdalena Kuzma (PO)
Caroline Ingre (SE)
Dorothee Lule (GE)

ENCALS executive board

Leonard van den Berg (NL) - chair
Orla Hardiman (IR) - co-chair
Adriano Chio (IT) - treasurer
Philip van Damme (BE)
Markus Weber (SW)
Monica Povedano (SP)
Peter Andersen (SE)
Francois Salachas (FR)
Magdalena Kuzma (PO)
Sharon Abrahams (SC)
Julian Grosskreutz (GE)
Ammar Al-Chalabi (UK)
Suzanne Petri (GE)
Vincenzo Silani (IT)
Philippe Corica (FR)
Blaz Kortnik (SL)
Martin Turner (UK)
Christopher McDermott (UK)
Caroline Ingre (SE)

Programme at a glance

	Agenda	Moderators
Monday 17 June		
09:00-11:45	Registration	
11:45-12:45	Lunch	
12:45-13:15	Welcoming words - Caroline Ingre and Leonard van den Berg	
13:15-14:30	Session 1 - Population and disease registries and Epidemiology Invited Speaker: Fang Fang	Adriano Chio and Fang Fang
14:30-15:00	Break	
15:00-16:15	Session 2 - Clinical Invited Speaker: Julian Grosskreutz and Philip Van Damme	Caroline Ingre and Thomas Meyer
16:15-16:45	Break	
16:45-17:30	Rapid Fire presentations A - Clinical	Magdalena Kuzma
17:30-18:30	Poster Session A	
Tuesday 18 June		
08:30-9:45	Session 3 - Pre-symptomatic changes and Imaging Invited Speaker: Joke de Vocht	Dorothee Lule and Sharon Abrahams
09:45-10:15	Break	
10:15-11:15	Session 4 - Genetics Invited Speaker: Peter Andersen	Jan Veldink and Philippe Corcia
11:45-12:30	DEBATE Topic: ALS future: Targeted VS Untargeted/Cocktail treatments? Angela Genge vs Pamela Shaw	Leonard van den Berg
14:00-15:15	Session 5 - Clinical trials and biomarkers Invited speaker: Chris McDermott	Martin Turner and Orla Hardiman
15:15-15:45	Break	
15:45-17:00	Platform presentation on trials: Amylyx (Phoenix), Ferrer (ADORE) and Humanitas Research Hospital (TUDCA trial)	Orla Hardiman and Ammar Al-Chalabi
17:00-17:45	Panel Discussion - about the New Std of Care Panel = Leonard van den Berg, Jeremy Shefner, Angela Genge, Pamela Shaw	Orla Hardiman and Ammar Al-Chalabi
17:45-18:45	Poster Session B	
19:45-24:00	Gala dinner	
Wednesday 19 June		
09:00-10:15	Session 6 - Biomarkers - Basic and translational Invited Speaker: Leonard Petrucelli	Philipe Van Damme and Sebastian Levandowski
10:15-10:45	Rapid Fire presentations B - Basic	Monica Povedano
10:45-11:15	Break	
11:15-11:30	EU ALS Coalition	Andrea Calvo
11:30-11:50	Industry Update , John Ravits	Andrea Calvo
11:50-12:00	Himalaya Trial , Nazem Atassi	Andrea Calvo
12:00-12:20	Borje Salming Award for best Rapid Fire Presentation , Ulf Hedin	Caroline Ingre
12:00-13:30	Lunch and posters	
13:30-14:45	Session 7 - Cellular, Molecular Biology, Dx and animal model Invited Speaker: Don Cleveland	Eva Hedlund and Jeroen Pasterkamp
14:45-15:15	Young Investigator and Poster Award	Ammar Al-Chalabi and Caroline Ingre
15:15-15:30	Wrap-up and announce of the next year	Leonard van den Berg, Caroline Ingre and Adriano Chio

Scientific programme

Monday 17th of June

09:00 - 11:45 Registration

11:45 - 12:45 Lunch

12:45-13:15 **Welcoming words**

Leonard van den Berg and Caroline Ingre

13:15-14:30 **Session 1 - Population and disease registries and Epidemiology**

Moderators: *Adriano Chio and Fang Fang*

Invited speaker: *Fang Fang*

1. Survival of ALS patients has increased over time: results from a long-standing register.

Rosario Bvasta

2. Increased incidence of motor neuron disease in Sweden: a population-based study during 2002-2021

Sofia Imrell

3. Epidemiology of Amyotrophic Lateral Sclerosis in Catalonia (Spain): 2015-2020

Sergio Vidal Notari

4. Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway – prevalence, ancestry, clinical and demographic variables

Helle Hoyer

5. A population-based disease mapping of ALS incidence in the Republic of Ireland from 1995 to 2022

Eanna Mac Domhnaill

14:30-15.00 **Break**

15:00-16:15 **Session 2 - Clinical**

Moderators: *Caroline Ingre and Thomas Meyer*

Invited speakers: *Julian Grosskreutz and Philip van Damme*

6. Single-cell transcriptomics reveal the presence of clonally expanding T cells in ALS

ZhenZhen Chen

7. Glymphatic dysfunction occurs across clinical phenotypes of motor neuron disease

Edoardo Gioele Spinelli

8. Brain metabolic features of FUS-ALS: a 2-[18F]FDG-PET study

Antonio Canosa

9. Sex Differences in Amyotrophic Lateral Sclerosis Survival and Progression: A Multidimensional Analysis

Maurizio Grassano

10. Neurofilament content of patient sensory skin axons reflects ALS progression

Janina von der Gablentz

11. Understanding How Cognitive and Behavioural Impairments Affect the Mental Capacity to Make Treatment Decisions in ALS.

Milena Contreras

Scientific program

16:15-16:45 Break

16:45-17:30 **Rapid Fire Presentations A - Clinical**

Moderator: *Magdalena Kuzma*

I. FDG-PET clustering analysis in Amyotrophic Lateral Sclerosis.

Joke de Vocht

II. Targeting the energy deficit in ALS - the LIPCAL-ALS II study

Johannes Dorst

III. Rare variants in the genetic background modulate risk and phenotype in ALS

Maurizio Grassano

IV. Cognitive Deficits in ALS patients with SOD1 mutations

Ivar Winroth

V. Physical activity, fitness and long-term risk of amyotrophic lateral sclerosis - a prospective cohort study

Anders Myhre Vaage

VI. Exploring the Genetic Underpinnings of Cognition in ALS through Multi-Trait GWAS Analysis

Emrah Kacar

VII. Longitudinal cognitive assessment using the Cumulus home-based EEG platform in ALS and FTD.

Emmet Costello

VIII. Defining functional brain network changes in ALS at higher temporal resolution

Alicia Northall

IX. Associations between resting-state electroencephalographic (EEG) measures and cognitive functions in ALS: a preliminary region-specific analysis

Serena Plaitano

X. Association study on HERV-K genomic insertions in Amyotrophic Lateral Sclerosis

Simon Topp

XI. Is a brief apathy assessment useful in motor neuron disease clinics?

Ratko Radakovic

XII. Investigating the potential of apathy as a predictor for ALS trial-participation.

Juliette Foucher

XIII. Education mediates the association between motor and cognitive-behavioural features in non-demented ALS patients

Edoardo Nicolo Aiello

XIV. An update on the role of autoantibodies against neurofilaments in amyotrophic lateral sclerosis (ALS)

Ellie Sturme

XV. BRAINTEASER Project: Enhancing Amyotrophic Lateral Sclerosis Care through Remote Monitoring and Artificial Intelligence Integration

Ines Alves

Scientific program

17:30-18:30 **Poster Session A**

08:30-9:45 **Session 3 - Pre-symptomatic changes and Imaging**

Moderators: *Dorothee Lule and Sharon Abrahams*

Invited speaker: *Joke de Vocht*

12. A comparison of frameworks for identifying cognitive and behavioural impairment in pre-symptomatic ALS

Caroline McHutchison

13. ECAS correlation with metabolic alterations on FDG-PET imaging in ALS patients

Linn Oijerstedt

14. QSM-detected iron accumulation in the cerebellar gray matter selectively predicts executive dysfunction in non-demented ALS patients

Claudia Morelli

15. Cognitive endophenotypes and C9orf72 in familial ALS: a longitudinal study

Colm Peelo

09:45-10:15 Break

10:15-11:15 **Session 4 - Genetics**

Moderators: *Jan Veldink and Philippe Corcia*

Invited speaker: *Peter Andersen*

16. Multiomic analysis to identify the genetic basis of amyotrophic lateral sclerosis

Calum Harvey

17. Plasma extracellular vesicle Tau and TDP-43 as diagnostic biomarkers in FTD and ALS

Anja Schneider

18. Using Irish Clan Genomics to Interrogate the Biological Overlap between Amyotrophic Lateral Sclerosis and Neuropsychiatric Disorders

Ciara O'Donoghue

19. Genome-wide screen for genetic modifiers in ALS progression

Ramona Zwamborn

20. The shared ancestry between the C9orf72 hexanucleotide repeat expansion and intermediate-length alleles using haplotype sharing trees and HAPTK

Osmo Rautila

11:15-11:45 Break

11:45-12:30 **Debate: "ALS future: Targeted vs. Untargeted/Cocktail treatments?"**

Moderator: *Leonard van den Berg*

Invited speakers: *Angela Genge and Pamela Shaw*

12:30-14:00 Lunch

14:00-15:15 **Session 5 - Clinical trials and biomarkers**

Moderators: *Martin Turner and Orla Hardiman*

Invited speaker: *Christopher McDermott*

Scientific program

21. Identification of proteomic clusters in the CSF of sporadic ALS patients

Laura Tzeplaeff

22. Combined rescue of STMN2 and UNC13A mis-splicing in ALS using a novel therapeutic approach

Puja Mehta

23. Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis – a longitudinal multicenter study

Thomas Meyer

24. Using ALS patient-derived astrocytes to identify patient stratification biomarkers in response to a promising multi-target drug

Raquel Rua Martins

25. Skin innervation across ALS clinical stages: new biomarkers of disease progression and survival

Raffaele Dubbioso

26. Longitudinal analysis of T cells responses in amyotrophic lateral sclerosis

Solmaz Yazdani

15:15-15:45 Break

15:45-17:00 **Platform presentation on trials: Phoenix, ADORE and Humanitas Research Hospital (TUDCA trial)**

Moderators: *Ammar Al-Chalabi and Orla Hardiman*

Leonard van den Berg, Sabrina Paganoni and Alberto Albanese

17:00-17:45 **Panel Discussion - About the New Standard of Care**

Moderators: *Ammar Al-Chalabi and Orla Hardiman*

Leonard van den Berg, Jeremy Shefner, Angela Genge, Pamela Shaw

17:45-18:45 **Poster Session B**

19:45-24:00 Gala Dinner

09:00-10:15 **Session 6 - Biomarkers; Basic and translational**

Moderators: *Philipe van Damme and Sebastian Levandowski*

Invited speaker: *Leonard Petrucelli*

27. Stress granules and oxidation drive TDP-43 demixing in the cytoplasm

Jik Nijssen

28. Differential pathways of astrocyte toxicity in sporadic ALS

Katie Bowden

29. Investigating the metabolic crosstalk between senescent lymphocytes and microglia from patients with ALS

Victoria Tsang

30. Toxic gain-of-function mechanisms, but not C9orf72 haploinsufficiency impairs the autophagy pathway in C9orf72 ALS/FTD iPSC-derived motor neurons.

Jimmy Beckers

Scientific program

31. Targeting EGLN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response.

Christine Germeys

32. Exploring Metabolic Pathways in ALS: TDP-43, Mitochondria, and Ferroptosis Interplay

Miriam Ceron Codorniu

10:15-10:45 **Rapid Fire presentations B - Basic**

Moderator: *Monica Povedano*

XVI. Tbk1 mutant zebrafish show increased programmed cell death and dysregulation of critical pathways involved in Amyotrophic Lateral Sclerosis (ALS)

Quentin Raas

XVII. Characterising activity-related phenotypes in C9ORF72 iPSC MNs using optogenetics

Jiali Gao

XVIII. Impact of trauma on presymptomatic C9orf72 carriers and symptomatic patients using hiP-SC-derived organoids as a double-hit model of neurodegeneration

Karthik Baskar

XIX. NEK1 regulates ER-mitochondria contacts.

Natalie Pye

XX. Comprehensive DNA methylation analysis shows no age acceleration in amyotrophic lateral sclerosis.

Polina Merbaum

XXI. Dysregulation of muscle cholesterol homeostasis in amyotrophic lateral sclerosis

Flore Cheguillaume

XXII. Disruption of the Angiopoietin-like protein system associates lipid homeostasis with hypothalamic dysfunction in ALS

Sruthi Sankari Krishnamurthy

XXIII. Altered Expression of Membrane Proteins in C9orf72 Mutation-Associated ALS and FTD

Ursa Cercek

XXIV. Endothelial TDP-43 controls sprouting angiogenesis and vascular barrier integrity, and its deletion triggers neuroinflammation

Eloi Montanez

XXV. Activation of polo-like kinase 1 expression in spinal motor neurons underlies the increased vulnerability of spinal motor neurons in FUS-ALS

Andreas Hermann

10:45-11:15 Break

11:15-11:30

EU ALS Coalition

Moderator: *Andrea Calvo*

Speaker: *Julian Grosskreutz*

Scientific program

11:30-11:50 **Industry Update**
Moderator: *Andrea Calvo*
Speaker: *John Ravits*

11:50-12:10 **Himalaya trial**
Moderator: *Andrea Calvo*
Speaker: *Nazem Atassi*

12:10-12:20 **Borje Salming Award for best Rapid Fire Presentation**
Moderator: *Caroline Ingre*
Speaker: *Ulf Hedin*

12:20-13:30 Lunch and posters

13:30-14:45 **Session 7 - Cellular, Molecular Biology and Animal Model**
Moderators: *Eva Hedlund and Jeroen Pasterkamp*
Invited speaker: *Don Cleveland*

33. (GR)400 and (PR)400 knock-in mice show a conserved neuroprotective role of an extracellular matrix signature in C9ALS/FTD
Carmelo Milioto

34. C-myc dysregulation contributes to glia-to-neuron miscommunication in Amyotrophic Lateral Sclerosis and Frontotemporal dementia
Manuela Basso

35. A TBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in mice
David Brenner

36. Organellomics: AI-driven deep organellar phenotyping of human neurons
Eran Hornstein

37. Modelling ALS caused by KIF5A mutations in patient-derived motor neurons
Isabel Loss

38. The homeoprotein transcription factor ENGRAILED-1 allows for spinal α -Motoneurons protection and repair
Alain Prochiantz

14:45-15:15 **Young Investigator and Poster Award**
Ammar Al-Chalabi and Caroline Ingre

15:15-15:30 **Wrap-up and announce ENCALS 2025**
Leonard van den Berg, Caroline Ingre and Adriano Chio

Sponsors

The ENCALS meeting 2024 would not have been possible without our sponsors and their generous support!

PRINCIPAL



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



Sponsor advertisement



Biogen is proud to sponsor the 2024 ENCALS meeting.

[biogen.com](https://www.biogen.com)
May 2024. Biogen-241727.



ENCALS
European Network to Cure ALS

Sponsor advertisement

European Network to Cure ALS (ENCALS) meeting 2024



ENCALS MEETING

17th - 20th June 2024
Stockholm, Sweden

Overcoming Barriers in ALS

understanding needs and empowering people

Zambon invites you to its satellite symposium on:
Monday 17th June 2024 | 9.00 – 10.30 CET | Room Ragnar Granit in Biomedicum

09.00 – 09.05	Introduction Chairman: Prof. N. Ticozzi, Italy
09.05 – 09.15	Assessing daily ALS treatment: are there any gaps? Prof. M. Povedano, Spain
09.15 – 09.25	Clinical aspects: understanding current patient needs Prof. J. Grosskreutz, Germany
09.25 – 09.35	Empowering people with ALS: the impact of improved treatment explanations R. Marsden, United Kingdom
09.35 – 10.00	Open Discussion

THE SYMPOSIUM WILL FOCUS ON THE TREATMENT OF ALS AND ITS VARIOUS ASPECTS, WITH SPECIAL EMPHASIS ON THE UNIQUE NEEDS OF PATIENTS AND THEIR ACTIVE PARTICIPATION IN UNDERSTANDING TREATMENT AND TAKING CARE OF THEMSELVES.

The speakers will present thoughts and data to:

- deepening everyday ALS treatment, to assess whether any gaps are not promoting a proper management of patients and their specific needs.
- understanding of patients' clinical needs by examining the challenges that people with ALS face day by day, to provide insights for potentially more personalized and effective care strategies.
- celebrating patient empowerment in ALS treatment by exploring how improved explanations of treatment can provide patients with the knowledge they need to participate in their care actively.

Zambon

Sponsor advertisement

Improving patient lives. The Zambon commitment.

Our recently-created innovation hub – Zambon Biotech – is dedicated to finding **solutions for unmet needs** in disease spaces such as ALS where progress can be slow.

We continue to invest in the development of practical and **life-enhancing improvements** to patient care that align with our ultimate mission statement: **to make patients' lives better.**



Zambon

ENCALS
European Network to Cure ALS

Sponsor advertisement



argenx

Reaching Patients Through
Immunology Innovation

www.argenx.com
Together We Discover



MED-EU-CORP-2400001

Sponsor advertisement

For PTC Therapeutics, our 25-year history has centered on bold, transformative science that brings more moments to patients and their families living with rare diseases.

See how we are pushing the boundaries of innovation for amyotrophic lateral sclerosis (ALS) at www.ptcbio.com.

TRANSLATING SCIENCE

Transforming Lives

Extending life's moments for people living with rare diseases



Sponsor advertisement

Delivering on the
promise of
gene therapy



uniQure

Innovating to transform the lives of patients

uniQure.com

Sponsor advertisement



QurAlisTM
Neuro Pioneers on a Quest to Cure

QurAlis is a proud sponsor of
ENCALS 2024

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will alter the trajectory of ALS, FTD, and other neurodegenerative diseases.

QATM www.quralis.com

Sponsor advertisement

